Navigating the future of cell therapies with exec Kathryn Corzo

Kathryn Corzo is currently the president and chief operating officer of The Cambridge, UK–based synthetic biology company specializes in providing human cells for research, drug discovery and cell therapy.

Her previous roles include a stint as the head of development for oncology cell therapies at Takeda. She also led the North American Innovation Center and R&D Digital Accelerator at Sanofi and held a leadership role in Lilly’s oncology business unit.’s differentiated approach

Corzo’s decision to join was rooted in the company’s pioneering approach to cell therapy. “Joining became a clear choice,” she recalls. “The platform technology at offers a solution to some of the significant challenges in the cell therapy field, mainly by manufacturing consistent cells at scale, speed and reduced costs thus democratizing access to human cells.…

Read more
  • 0

Prominent cell and gene therapy vendors in 2023

[Image courtesy of catalin/Adobe Stock]

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030.

The burgeoning demand in the industry, along with an increasing number of FDA-approved therapies, is also fueling the growth of cell and gene therapy vendors offering tools and services for product development and manufacturing.

The following table includes notable vendors and suppliers active in the call and gene therapy marketplace. This curated selection of companies includes a brief overview of their focus areas.

We have a separate feature focused on companies with prominent cell and gene therapy development efforts.

Company Name Description Notable partnerships Founded He…
Read more
  • 0